Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies-Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus.
Katarzyna FischerHanna Przepiera-BędzakIwona BrzoskoMarcin SawickiAnna WaleckaMarek BrzoskoPublished in: Biomolecules (2022)
Patients with aPS and aPE are at risk of vascular involvement. Especially the presence of aPE may significantly increase the risk of thrombotic complications development in SLE patients without classical serological markers of APS. Finally, aPE might be used as a marker of disease activity and risk of renal injury development in this patient group. The classical atherosclerotic markers including lipid indices play an important role in complex analysis of cardiovascular risk in lupus patients and enable to identify patients at the highest risk and implement effective preventive, diagnostic and therapeutic procedures.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- end stage renal disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- cardiovascular disease
- type diabetes
- risk factors
- case report
- patient reported outcomes